Collier En Alliage Doré Ou Argenté Avec Pendentif En Franges Et… — recall A12/02551/24
EU Safety Gate (RAPEX) · France · 2024-09-06 · Serious risk
As described by EU Safety Gate (RAPEX): Collier En Alliage Doré Ou Argenté Avec Pendentif En Franges Et Strass Bohème, Chaîne De Clavicule A
🌐Machine-translated with AI — the facts come from the issuing authority’s own notice (linked on this page); this language version was translated automatically by an AI model and is not reviewed. The original-language notice is authoritative. How we use AI →
Reported risk: Le produit présente une concentration excessive de cadmium (valeurs mesurées jusqu'à : 0,062 % en poids). Le cadmium est nocif pour la santé humaine car il s'accumule dans l'organisme, peut endommager les reins et les os et peut provoquer un cancer. Le produit n'est pas conforme au règlement REACH.
Action taken by the authority
Type of economic operator taking notified measure
Other
Category of measure
Removal of this product listing by the online marketplace
Date of entry into force
08/07/2024
Machine translation. This page was translated automatically from the English record we hold of the issuing authority’s notice. The English original is shown below and the authority’s own notice is linked above — both take precedence over this translation.
Product Name (original English): Collier En Alliage Doré Ou Argenté Avec Pendentif En Franges Et Strass Bohème, Chaîne De Clavicule A
Risk Description (original English): The product has an excessive concentration of cadmium (measured values up to: 0.062%, by weight).
Cadmium is harmful to human health because it accumulates in the body, can damage the kidneys and bones and it may cause cancer.
.
Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.
ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.